Heterocyclic Compounds for Selective PI3K Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with PI3K-δ and PI3K-γ isoforms lack specificity, often affecting PI3K-β isoform activity, leading to unintended consequences and reduced efficacy.
Innovation Solution
Development of compounds that selectively inhibit PI3K-δ and/or PI3K-γ without affecting PI3K-β, utilizing specific chemical structures to modulate phosphatidyl inositol-3 kinase activity, thereby targeting specific disease conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for PI3K-δ/γ associated diseases are used, then disease conditions can be addressed, but PI3K-β isoform activity is also affected leading to unintended consequences
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (such as heterocyclic rings at particular positions, specific substituent patterns) that create selective binding affinity for PI3K-δ/γ isoforms while avoiding PI3K-β. This is achieved through careful modification of molecular properties at specific locations in the compound structure, enabling differential interaction with different kinase isoforms based on their unique binding site characteristics.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters including heterocyclic ring type (e.g., pyridine, pyrimidine, triazine), substituent nature and position, molecular size, and electronic properties. These parameter modifications allow tuning of the compound's selectivity profile to achieve preferential inhibition of PI3K-δ/γ over PI3K-β, thereby resolving the contradiction between efficacy and off-target effects.
2Adaptability or versatility
If non-selective PI3K inhibitors are used, then broad kinase activity can be modulated, but specificity for target isoforms is reduced
Solution Approach 1:
The patent applies segmentation by dividing the kinase family into distinct isoform groups (PI3K-δ/γ versus PI3K-β) and designing compounds that selectively target specific segments. The molecular structure is optimized to recognize isoform-specific features, creating a segmented inhibition pattern where different kinase isoforms are differentially affected based on their structural and functional characteristics.
Solution Approach 2:
The patent uses intermediary principles by introducing specific molecular mediators (heterocyclic compounds with particular functional groups) that act as intermediaries between the inhibitor and the kinase isoforms. These intermediary structures facilitate selective recognition and binding to PI3K-δ/γ while preventing interaction with PI3K-β, thereby achieving both versatility in targeting and precision in selectivity.
3Manufacturing precision
If selective PI3K-δ/γ inhibitors are developed, then treatment specificity is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies partial action by focusing selectivity optimizations on critical structural elements that most significantly impact isoform discrimination, rather than attempting to optimize all possible molecular parameters. By concentrating efforts on key heterocyclic ring selections and primary substituent patterns, the patent achieves high selectivity without unnecessarily complicating the overall molecular structure.
Solution Approach 2:
The patent employs composite material principles by combining well-established heterocyclic building blocks (such as pyridine, pyrimidine, triazine rings) with known pharmacophoric elements in specific configurations. This composite approach allows construction of selective inhibitors using modular, characterized components, thereby achieving high isoform selectivity while maintaining reasonable structural complexity through the use of recognized molecular building blocks.
Data Source
AI summary
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.